Cristofanilli M, Slamon DJ, Ro J, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. ESMO 2018, abstract LBA2_PR.
Icotinib versus chemotherapie als adjuvante behandeling stadium II-IIIA EGFR-gemuteerd NSCLC
jan 2022 | Longoncologie